CervoMed Inc.
CRVOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 20, 2026 | Roth Capital | $7.00(+158%) | $2.71 | TheFly | |
| May 18, 2026 | Roth Capital | $9.00(+196%) | $3.04 | TheFly | |
| Nov 5, 2025 | H.C. Wainwright | Raghuram Selvaraju | $25.00(+256%) | $7.02 | TheFly |
| Oct 17, 2025 | Roth Capital | $20.00(+163%) | $7.60 | TheFly | |
| Aug 12, 2025 | Roth Capital | Boobalan Pachaiyappan | $16.00(+70%) | $9.41 | TheFly |
| Sep 18, 2024 | Loop Capital Markets | Danill Gataulin | $55.00(+1048%) | $4.79 | StreetInsider |
| Sep 18, 2024 | Chardan Capital | Daniil Gataulin | $55.00(+1048%) | $4.79 | TheFly |
| Apr 8, 2024 | Canaccord Genuity | Sumant Kulkarni | $65.00(+969%) | $6.08 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2026 |
| Canaccord Genuity | maintain | Buy | Aug 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 23, 2026 |
| D. Boral Capital | maintain | Buy | Apr 22, 2026 |
| D. Boral Capital | maintain | Buy | Apr 8, 2026 |
| D. Boral Capital | maintain | Buy | Mar 19, 2026 |
| Roth Capital | maintain | Buy | Mar 18, 2026 |
| Chardan Capital | maintain | Buy | Mar 18, 2026 |
| D. Boral Capital | maintain | Buy | Mar 16, 2026 |
| Chardan Capital | maintain | Buy | Mar 5, 2026 |
| D. Boral Capital | maintain | Buy | Mar 4, 2026 |
| D. Boral Capital | maintain | Buy | Feb 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2025 |
| D. Boral Capital | maintain | Buy | Dec 5, 2025 |
| D. Boral Capital | maintain | Buy | Dec 2, 2025 |
| D. Boral Capital | maintain | Buy | Nov 11, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Nov 5, 2025 |
| D. Boral Capital | maintain | Buy | Nov 4, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Sep 8, 2025 |
| D. Boral Capital | maintain | Buy | Aug 18, 2025 |
| Roth Capital | maintain | Buy | Aug 12, 2025 |
Earnings History
Next report: Mar 12, 2027 · EPS est. $-0.64| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.39 | $-0.49 | — | $50.0K |
| Aug 10, 2026 | $-0.64 | $-0.87 | — | $50.0K |
| May 18, 2026 | $-0.86 | $-0.90 | — | $71.4K |
| Mar 13, 2026 | $-0.88 | $-0.79 | $6.5K | $90.8K |
| Nov 7, 2025 | $-0.84 | $-0.68 | $322.6K | $1.2M |
| Aug 8, 2025 | $-0.70 | $-0.61 | $1.8M | $1.4M |
| May 12, 2025 | $-0.56 | $-0.60 | $1.9M | $1.7M |
| Mar 17, 2025 | $-0.80 | $-0.67 | $2.2M | $1.5M |
News
Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer's Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB
CervoMed Inc. (NASDAQ:CRVO) reported early results from its Phase 2a clinical study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
CervoMed (NASDAQ: CRVO - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Monday, MarketBeat reports. A number of other brokerages have also weighed in on CRVO. Wall Street Zen upgraded CervoMed from a "strong sell" rating to a "sell" rating in a research
CervoMed Inc. (NASDAQ: CRVO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has issued a
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker …